Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men (OHH)

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: September 10, 2010
Last updated: October 16, 2013
Last verified: March 2013

This study is designed as a 2-part study, with Part 1 being open-label to best determine the appropriate dose levels to use in Part 2, which has a randomized, double-blind, placebo controlled design. The study aims to assess the safety and tolerability of BGS649, and determine whether or not BGS649 is able to normalize testosterone levels and improve insulin sensitivity in obese, hypogonadotropic hypogonadal (OHH) men

Condition Intervention Phase
Obese Hypogonadotropic Hypogonadism
Drug: Investigational new drug company code: BGS649
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: An Open-label Dose Finding Study Followed by a Parallel Group, Randomized, Double-blind Study to Evaluate the Safety, Tolerability and Pharmacodynamics of 12 Week BGS649 Treatment in Obese, Hypogonadotropic Hypogonadal Men

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Normalization of testosterone levels [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Determine effect of BGS649 on insulin sensitivity [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Safety and tolerability of BGS649 in obese men [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
  • Assess the pharmacodynamic effect of BGS649 on glucose, insulin and lipid metabolism, and body composition [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 239
Study Start Date: August 2010
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BGS649 Drug: Investigational new drug company code: BGS649
Placebo Comparator: Placebo to BGS649 Drug: Placebo


Ages Eligible for Study:   30 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males who meet the criteria of obese, hypogonadotropic hypogonadism defined as:

    • Patients with a Body Mass Index (BMI) ≥ 30 kg/m2
    • Patients with a morning serum total testosterone level < 300 ng/dL on at least two separate occasions during the Screening and/or Baseline periods.
    • Patients with inappropriately low gonadotropins at screening given the low testosterone:
  • Luteinizing hormone (LH) ≤ ULN
  • Follicle stimulating hormone (FSH) ≤ ULN
  • Estradiol within or above the normal range (defined as ≥ LLN of the approved assay)

    • Normal hypothalamic/pituitary function, including:
  • Prolactin: within the normal range
  • Thyroid stimulating hormone (TSH): within the normal range
  • Ferritin: within the normal range
  • Patients agree to use a barrier method of contraception (e.g., condom), for the duration of the study and for at least 3 months following their Study Completion visit to prevent BGS649 exposure to their partners.

Exclusion Criteria:

  • Patients with hypogonadism, not related to obesity or as a result of other underlying issues
  • Patients with significant major organ class illness (e.g. kidney or liver disease).
  • Other protocol-defined inclusion/exclusion criteria may apply
  Contacts and Locations
Please refer to this study by its identifier: NCT01200862

United States, Arizona
Novartis Investigative Site
Tucson, Arizona, United States, 85712
United States, California
Novartis Investigative Site
San Diego, California, United States, 92120
United States, Florida
Novartis Investigative Site
Miramar, Florida, United States, 33025
United States, Utah
Novartis Investigative Site
West Valley City, Utah, United States, 84120
Canada, Quebec
Novartis Investigative Site
Montreal, Quebec, Canada, H3X 2H9
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided

Responsible Party: Novartis ( Novartis Pharmaceuticals ) Identifier: NCT01200862     History of Changes
Other Study ID Numbers: CBGS649A2204
Study First Received: September 10, 2010
Last Updated: October 16, 2013
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Keywords provided by Novartis:

Additional relevant MeSH terms:
Gonadal Disorders
Endocrine System Diseases
Nutrition Disorders
Body Weight
Signs and Symptoms processed this record on April 15, 2014